Russell Investments Group, Ltd. Eiger Bio Pharmaceuticals, Inc. Transaction History

Russell Investments Group, Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 05, 2022	SELL	$3.84 - $9.74 $1.23 Million - $3.12 Million	-320,753 Closed	0 $0
Q4 2021 Jan 21, 2022	BUY	$5.12 - $8.19 $921,395 - $1.47 Million	179,960 Added 127.82%	320,753 $1.66 Million
Q3 2021 Nov 08, 2021	BUY	$6.68 - $9.1 $208,249 - $283,692	31,175 Added 28.44%	140,793 $940,000
Q2 2021 Aug 04, 2021	SELL	$7.82 - $9.23 $343,211 - $405,095	-43,889 Reduced 28.59%	109,618 $932,000
Q1 2021 May 10, 2021	BUY	$8.44 - $12.66 $757,380 - $1.14 Million	89,737 Added 140.72%	153,507 $1.36 Million
Q4 2020 Feb 08, 2021	SELL	$7.98 - $12.29 $29,541 - $45,497	-3,702 Reduced 5.49%	63,770 $783,000
Q3 2020 Nov 09, 2020	BUY	$7.96 - $12.42 $340,441 - $531,190	42,769 Added 173.13%	67,472 $548,000
Q2 2020 Aug 05, 2020	BUY	$5.4 - $13.37 $50,533 - $125,116	9,358 Added 60.98%	24,703 $237,000
Q1 2020 May 06, 2020	BUY	$4.91 - $14.7 $75,343 - $225,571	15,345 New	15,345 $104,000

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

Stay updated on Russell Investments Group, Ltd. with notifications on news.